Showing results (1171-1180 of 1,222) with videos related to
Sort By:
Pageof 123
Lung Cancer (Amsterdam, Netherlands)|July 26, 2021
Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusionsSebastian Mondaca, Emily S Lebow, Azadeh Namakydoust, et al.Cancer Discovery|November 10, 2022
Molecular Characterization of Acquired Resistance to KRASG12C-EGFR Inhibition in Colorectal CancerRona Yaeger, Riccardo Mezzadra, Jenna Sinopoli, et al.Nature Genetics|June 3, 2020
Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapyAlejandro Jiménez-Sánchez, Paulina Cybulska, Katherine LaVigne Mager, et al.Cancer Research|December 4, 2016
IDH2 Mutations Define a Unique Subtype of Breast Cancer with Altered Nuclear PolaritySarah Chiang, Britta Weigelt, Huei-Chi Wen, et al.Journal of the National Cancer Institute|July 30, 2020
Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic EfficacyKenneth L Pitter, Dana L Casey, Yue C Lu, et al.Nature Communications|May 10, 2018
Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomasFelipe C Geyer, Anqi Li, Anastasios D Papanastasiou, et al.Frontiers in Medicine|October 16, 2023
Corrigendum: Home-based exercise program in the indeterminate form of Chagas disease (PEDI-CHAGAS study): a study protocol for a randomized clinical trialMauro F F Mediano, Leonardo G Ribeiro, Rudson S Silva, et al.Frontiers in Medicine|January 23, 2023
Home-based exercise program in the indeterminate form of Chagas disease (PEDI-CHAGAS study): A study protocol for a randomized clinical trialMauro F F Mediano, Leonardo G Ribeiro, Rudson S Silva, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2017
HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast CancerXiaowei Xu, Carmine De Angelis, Kathleen A Burke, et al.Nature Cancer|September 1, 2020
Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitorsPedram Razavi, Maura N Dickler, Payal D Shah, et al.Pageof 123